Targeted Photodynamic Virotherapy Armed with a Genetically Encoded Photosensitizer

Kiyoto Takehara¹, Hiroshi Tazawa¹,2, Naohiro Okada¹, Yuuri Hashimoto¹, Satoru Kikuchi¹, Shinji Kuroda¹, Hiroyuki Kishimoto¹, Yasuhiro Shirakawa¹, Nobuhiro Narii³, Hiroyuki Mizuguchi², Yasuo Urata⁴, Shunsuke Kagawa¹, and Toshiyoshi Fujiwara¹

Abstract

Photodynamic therapy (PDT) is a minimally invasive antitumor therapy that eradicates tumor cells through a photosensitizer-mediated cytotoxic effect upon light irradiation. However, systemic administration of photosensitizer often makes it difficult to avoid a photosensitive adverse effect. The red fluorescent protein KillerRed generates reactive oxygen species (ROS) upon green light irradiation. Here, we show the therapeutic potential of a novel tumor-specific replicating photodynamic viral agent (TelomeKiller) constructed using the human telomerase reverse transcriptase (htERT) promoter. We investigated the light-induced antitumor effect of TelomeKiller in several types of human cancer cell lines. Relative cell viability was investigated using an XTT assay. The in vivo antitumor effect was assessed using subcutaneous xenografted tumor and lymph node metastasis models. KillerRed accumulation resulted in ROS generation and apoptosis in light-irradiated cancer cells. Intratumoral injection of TelomeKiller efficiently delivered the KillerRed protein throughout the tumors and exhibited a long-lasting antitumor effect with repeated administration and light irradiation in mice. Moreover, intratumorally injected TelomeKiller could spread into the regional lymph node area and eliminate micrometastasis with limited-field laser irradiation. Our results suggest that KillerRed has great potential as a novel photosensitizer if delivered with a tumor-specific virus-mediated delivery system. TelomeKiller-based PDT is a promising antitumor strategy to efficiently eradicate tumor cells.

Introduction

Photodynamic therapy (PDT) is a minimally invasive antitumor strategy for the induction of tumor-specific cytotoxicity through the accumulation of photosensitizers and subsequent light irradiation (1, 2). Light irradiation of a specific wavelength induces the photosensitizer-mediated generation of reactive oxygen species (ROS) and subsequent cytotoxicity in tumor cells. Currently, photosensitizers such as Photofrin, Talaporfin (Laserphyrin), and 5-aminolevulinic acid are frequently used for anticancer PDT in a clinical setting (2). Although Photofrin is the most popular photosensitizer used worldwide, there are a number of unsolved problems with the use of photosensitizers, including a long-lasting skin photosensitivity and low efficacy of elimination of tumor cells. The lack of sufficient and continuous accumulation of photosensitizers in tumor tissues often makes it difficult to eradicate tumor cells by PDT. Therefore, the development of a novel strategy for more efficient and persistent tumor-specific accumulation of photosensitizers in tumor tissues is required to improve the antitumor effect of PDT.

KillerRed is a novel bioengineered dimeric red fluorescent protein that was obtained from genetically engineered green fluorescent protein (GFP) homologs (3). KillerRed generates ROS upon green light irradiation with fluorescence excitation/emission maxima at 585/610 nm (3), suggesting a therapeutic potential of KillerRed as a novel photosensitizer. In fact, recent reports have shown that KillerRed, but not other red fluorescent proteins, can induce a phototoxic effect in a light-mediated manner in Escherichia coli bacteria (3, 4) and in normal human kidney 293T cells (3, 5). Moreover, some recent reports have suggested the therapeutic potential of KillerRed as a novel photosensitizer against tumor cells (6, 7). If KillerRed protein was efficiently and persistently accumulated in tumor cells, then green light irradiation would induce a KillerRed-mediated cytotoxic effect. However, a delivery system for tumor-specific KillerRed accumulation is required to develop KillerRed-based photodynamic anticancer therapy.

Genetically engineered armed oncolytic viruses that express several types of therapeutic transgenes have recently been reported that were aimed at enhancing the antitumor effect of an oncolytic virus (8, 9). A telomerase-specific replicative oncolytic adenovirus (OBP-301, Telomelysin), in which the human telomerase reverse transcriptase (htERT) promoter element drives E1 gene expression, selectively replicates in tumor cells and lyses infected cells (10–12). In addition to its inherent cytotoxicity, Telomelysin can also be used as vectors for gene delivery (13–16). We further modified Telomelysin to contain the KillerRed gene for targeted photodynamic virotherapy. Here we show the therapeutic
potential of a telomerase-specific conditionally replicating adenovirus expressing KillerRed, termed TelomeKiller, by using a subcutaneous xenografted tumor model and an intraperitoneal lymph node metastasis model.

Materials and Methods

Cell lines
The human non–small cell lung cancer cell line H1299 and the human colon cancer cell lines HCT116 and HT-29 were obtained from the American Type Culture Collection. HCT-116-GFP cells that express GFP protein were obtained from AntiCancer Inc. (San Diego). H1299 and HCT116-GFP cells were maintained in RPMI-1640 medium. HCT116 and HT-29 cells were maintained in McCoy’s 5A and Dulbecco’s modified Eagle medium, respectively. All media were supplemented with 10% fetal bovine serum, 100 U/mL penicillin and 100 mg/mL streptomycin. The cells were routinely maintained at 37°C in a humidified atmosphere with 5% CO2 and not cultured for more than 5 months following resuscitation. The authentication was not performed by the authors. H1299 cells stably transfected with pKillerRed-mem (H1299-KillerRed) or pTurboFP635 (H1299-TurboFP635) or cotransfected with pKillerRed-mem and pEGFP (H1299-KillerRed-EGFP) were established by a limiting dilution method.

Recombinant adenoviruses
The recombinant nonreplicative E1/E3-deleted adenovirus expressing cytotoxic KillerRed (Ad-KillerRed) or noncytotoxic TurboFP635 (Ad-TurboFP635) was generated by insertion into the virus of the KillerRed or the TurboFP635 gene expression cassette, respectively, which was excised from the membrane-targeted KillerRed expression plasmid pKillerRed-mem (Evrogen) or the TurboFP635 expression plasmid (Evrogen) (Supplementary Fig. S1A). The telomerase-specific conditionally replicating adenovirus OBP-301 (Telomelysin), in which the promoter element of the hTERT gene drives the expression of E1A and E1B genes that are linked with an internal ribosome entry site (IRES), was previously constructed and characterized (refs. 10, 11; Supplementary Fig. S1A). For tumor-specific induction of KillerRed expression by OBP-301, the KillerRed-expressing conditionally replicating replication-competent adenovirus (TelomeKiller) was generated, in which a KillerRed expression cassette was inserted into the E3 region of OBP-301 (Supplementary Fig. S1B). Recombinant adenoviruses were purified using cesium chloride step gradients, their titers were determined by a plaque-forming assay using 293 cells, and they were stored at −80°C.

Detection of intracellular reactive oxygen species
To detect the generation of intracellular reactive oxygen species (ROS), 2',7'-dichlorodihydrofluorescein Diacetate (DCF-DA; Wako) was used. H1299 and H1299-KillerRed cells were incubated with DCF-DA (20 μmol/L) for 30 minutes at 37°C, and after washing twice with phosphate buffered saline (PBS), fluorescence was detected at 485/528 nm using a fluorescence microplate reader.

Immunocytochemistry for cleaved caspase-3
H1299-KillerRed cells were irradiated with green light (200 mW/cm²) through semrock fluorescence filter (542–582 nm; TxRed-4040C-000) for 60 minutes (720 J/cm²) using a fluorescence microscope (IX71; Olympus). The irradiance was measured using power meter, PM100D (Thorlabs, Inc.). Twenty-four hours after irradiation, the H1299-KillerRed cells were fixed with 3% paraformaldehyde solution for 15 minutes and permeabilized with 0.2% Triton X-100 in Blocking-One solution (Nacalai Tesque) for 5 minutes. After washing with PBS, cells were incubated with rabbit anticleaved caspase-3 monoclonal antibody (Cell Signaling Technology) and FITC-conjugated secondary antibody. After nuclear staining with DAPI, the cells were observed using a fluorescent microscope (IX71; Olympus).

Cell viability assay
Cells were seeded on 96-well plates at a density of 3 × 10³ cells/well 24 hours before infection and were infected with Ad-KillerRed or Ad-TurboFP635 at multiplicity of infections (MOIs) of 0, 10, 50, 100, 500, or 1000 plaque-forming units (PFU)/cell or with TelomeKiller at MOIs of 0, 10, 50, or 100 PFU/cell. Cells were irradiated with 590 nm yellow-orange LED light (180 mW/cm²) for 60 minutes (648 J/cm²) on the first 2 days following virus infection. Cell viability was determined immediately after irradiation using the Cell Proliferation Kit II (Roche Molecular Biochemicals), which is based on an XTT (sodium 3'-[1-(phenylaminocarbonyl)-3,4-tetrazolium]-bis(4-methoxy-6-nitro) benzene sulfonic acid hydrate) assay, according to the manufacturer’s protocol. Cell viability of Ad-KillerRed- or Ad-TurboFP635-infected cells was calculated by dividing the viability of irradiated cells by that of nonirradiated cells, and the viability of TelomeKiller-infected cells was calculated as the percentage of viable infected cells divided by that of viable noninfected cells.

Western blot analysis
H1299 or H1299-KillerRed cells were seeded on six-well plates at a density of 5 × 10⁴ cells/well. H1299 cells were further infected with Ad-KillerRed or TelomeKiller at an MOI of 100. Whole cell lysates were prepared in a lysis buffer [50 mmol/L Tris-HCl (pH 7.4), 150 mmol/L NaCl, 1% Triton X-100] containing a protease inhibitor cocktail (Complete Mini; Roche Applied Science). Proteins were electrophoresed on 10% SDS polyacrylamide gels and transferred to polyvinylidene difluoride membranes (Hybond-P; GE Healthcare). Blots were blocked with 5% nonfat dry milk in Tris-buffered saline and 0.1% Tween-20, pH 7.4 (TBS-T) at room temperature for 30 minutes. The primary antibodies used were: rabbit anti-KillerRed polyclonal antibody (Evrogen) and mouse anti-β-actin monoclonal antibody (Sigma-Aldrich). The secondary antibodies used were: horseradish peroxidase-conjugated antibodies against rabbit IgG (GE Healthcare) or mouse IgG (GE Healthcare). Immunoreactive bands on the blots were visualized using enhanced chemiluminescence substrates (ECL Prime; GE Healthcare).

In vivo subcutaneous HCT116 tumor model
The experimental protocol was approved by the Ethics Review Committee for Animal Experimentation of our institution. HCT116-GFP xenograft tumors were produced on the left flank of 6-week-old female BALB/c-nu/nu mice by subcutaneous injection of 3 × 10⁶ cells in 50 μL of PBS with 50 μL of Matrigel basement membrane matrix (BD Biosciences). As the tumors grew to a diameter of 6 to 7 mm, TelomeKiller was injected intratumorally at an MOI of 1.0 × 10⁶ PFU/100 μL. Mice were anesthetized by subcutaneous injection of ketamine (100 mg/kg) and xylazine (10 mg/kg). PDT was performed using a 589 nm diode pumped solid state laser (Changchun New Industries Optoelectronics Technology Co., Ltd.). The mice were irradiated with
yellow-orange laser (300 mW/cm²) for 30 minutes (540 J/cm²). Virus was injected on days 0, 7, and 14 and laser irradiation was performed on days 3 and 4, 10 and 11, and 17 and 18. The perpendicular diameter of each tumor was measured every 3 or 4 days, and tumor volume was calculated using the following formula: tumor volume (mm³) = $a \times b^2 \times 0.5$, where $a$ is the longest diameter, $b$ is the shortest diameter, and 0.5 is a constant for calculation of the volume of an ellipsoid. The tumors were excised on day 28.

In vivo HCT116-GFP lymph node metastasis model

The implantation procedures for submucosally invasive early human rectal cancer xenograft tumors have recently been established (17). Briefly, cell suspensions of HCT116-GFP cells at a density of $3 \times 10^6$ cells in 25 μL of PBS with 25 μL of Matrigel basement membrane matrix were slowly injected into the submucosal layer of the rectum using a 29-gauge needle. Ten days later, as the rectal tumors grew to a diameter of about 5 mm, $1.0 \times 10^8$ PFU/50 μL of TelomeKiller were directly injected into the rectal tumors. Three days after virus injection, laparotomy was performed and GFP-expressing metastatic para-aortic or iliac lymph nodes were irradiated with the laser at 300 mW/cm² for 30 minutes (540 J/cm²). Twenty-one days after virus injection, the mice were euthanized to assess tumor progression in the lymph nodes. In vivo fluorescence images were taken using a stereo microscope (SZX16; Olympus) and a microscope digital camera (DP71; Olympus). GFP fluorescence intensity was analyzed using VisionWorks LS software for the quantification of lymph node metastasis.

Statistical analysis

Data are expressed as means ± SD. Significant differences were assessed using Student t test. Statistical significance was defined when the $P$ value was less than 0.05.
Results

KillerRed-mediated apoptosis induction in human cancer cells via increased intracellular reactive oxygen species

To investigate whether KillerRed induces ROS and apoptosis in human cancer cells, human lung cancer H1299 cells that were stably transfected with a cytotoxic KillerRed-mem expression plasmid vector (H1299-KillerRed) or a noncytotoxic TurboFP635 expression plasmid vector (H1299-TurboFP635) were established. When parental H1299, H1299-KillerRed, and H1299-TurboFP635 cells were irradiated with green light for 60 minutes, a dramatic morphologic change to a rounded shape was observed in H1299-KillerRed cells, but not in H1299 or H1299-TurboFP635 cells (Fig. 1A). We further confirmed that H1299 cells stably cotransfected with KillerRed- and EGFP-expressing vectors (H1299-KillerRed-EGFP) showed morphologic changes following photobleaching during light irradiation (Supplementary Movie S1). Analysis of intracellular ROS using DCF-DA revealed that the intracellular amount of ROS was significantly increased in H1299-KillerRed cells after light irradiation compared to the parental H1299 cells (Fig. 1B). Moreover, immunocytologic analysis demonstrated that expression of the apoptosis-specific marker cleaved caspase-3 was increased in the light-irradiated H1299-KillerRed cells (Fig. 1C). These results suggest that KillerRed accumulation induces apoptotic cell death in association with oxidative stress in human cancer cells.

Photosensitive antitumor effect of KillerRed induced by a nonreplicative adenovirus

The observation of KillerRed-mediated apoptosis induction in light-irradiated cancer cells prompted us to develop a virus-mediated KillerRed delivery system as a novel photodynamic anticancer therapy. Because replication-deficient adenovirus vectors are frequently used to induce therapeutic genes such as tumor suppressor p53 (18) in human cancer cells in preclinical and clinical settings, we generated a replication-deficient adenovirus vector expressing cytotoxic KillerRed (Ad-KillerRed) or noncytotoxic TurboFP635 (Ad-TurboFP635; Supplementary Fig. S1A). Three types of human cancer cell lines (H1299, HCT116, HT-29) were infected with Ad-KillerRed or Ad-TurboFP635 at an MOI of 100. After infection for 48 hours, the virus-infected cells were irradiated with green light for 60 minutes (Fig. 2). The Ad-KillerRed-infected cancer cells showed photobleaching and morphologic change to a rounded shape and shrinkage after light irradiation. In contrast, Ad-TurboFP635-infected cancer cells showed no photobleaching and slight morphologic change to a rounded shape after light irradiation. To quantitatively compare the antitumor effect of Ad-KillerRed and Ad-TurboFP635, the viability of virus-infected human cancer cells with or without light irradiation was analyzed using an XTT assay. Infection with Ad-KillerRed at an MOI of 100 significantly decreased the viability of H1299 cells following photobleaching at 60 minutes after infection (Fig. 3A). Ad-KillerRed infection at high doses (MOIs of 100, 500, and 1000) significantly decreased the viability of H1299 and HCT116 cells after light irradiation, whereas Ad-KillerRed at MOI of more than 500 was needed to reduce the viability of HT-29 cells after light irradiation (Fig. 3B). In contrast, Ad-TurboFP635 infection did not affect the viability of human cancer cells after light irradiation (Fig. 3C). These results suggest that the adenovirus-mediated KillerRed delivery system is a useful method for induction of the KillerRed-mediated antitumor effect in human cancer cells in combination with light irradiation.
Profound antitumor effect of KillerRed induced by a conditionally replicating adenovirus

To induce KillerRed expression in human cancer cells in a more efficient and tumor-specific manner than could be achieved with Ad-KillerRed, we further generated a telomerase-specific conditionally replicating adenovirus that expressed KillerRed (TelomeKiller) (Supplementary Fig. S1B). When the expression level of KillerRed in Ad-KillerRed- and TelomeKiller-infected H1299 cells was compared using Western blot analysis, TelomeKiller cells induced higher KillerRed expression than Ad-KillerRed cells in a time-dependent manner (Fig. 4A). The KillerRed expression induced by the Ad-KillerRed cells was similar to that of the H1299-KillerRed stable transfectants. Under fluorescence microscopy, TelomeKiller efficiently induced red fluorescent KillerRed expression and morphologic change to a rounded shape in 3 different human cancer cell lines before light irradiation because TelomeKiller has cytopathic effect due to virus replication (Fig. 4B). After light irradiation, TelomeKiller-infected cancer cells showed photobleaching and morphologic change to shrinkage and destruction of cell membrane (Fig. 4B). Moreover, an XTT assay demonstrated that light irradiation significantly enhanced the TelomeKiller-mediated antitumor effect in HCT116 and HT-29 cells, whereas H1299 cells were highly sensitive to TelomeKiller infection alone (Fig. 4C). These results suggest that TelomeKiller-based KillerRed delivery system is a useful method for the induction of high KillerRed accumulation and for KillerRed-mediated antitumor effect in combination with light irradiation.

In vivo antitumor effect of TelomeKiller in an HCT116 xenograft tumor model in combination with light irradiation

Next, to evaluate the TelomeKiller-mediated in vivo antitumor effect, we first investigated the tumor distribution of KillerRed expression using subcutaneous HCT116 xenograft tumor models. TelomeKiller was injected at a concentration of $1.0 \times 10^5$ PFU/100 μl into the left tumor and 100 μl of PBS was injected into the right tumor. Four days after virus injection, fluorescence images were acquired under a fluorescence stereomicroscope. Slight KillerRed-mediated red fluorescence was observed throughout the body surface of the mice with TelomeKiller-infected tumor tissues (Fig. 5A). Analysis of isolated tumors indicated that red fluorescence was widely distributed within TelomeKiller-infected tumor tissues (Fig. 5B).
Based on the result of the KillerRed distribution experiment, we next assessed the in vivo antitumor effect of TelomeKiller in combination with light irradiation using this human HCT116 xenograft tumor model. HCT116 tumors were treated with (i) nothing (control), (ii) TelomeKiller injection alone, (iii) light irradiation alone, or (iv) combination therapy of TelomeKiller injection and light irradiation (Fig. 5C). Combination therapy of TelomeKiller and light irradiation significantly suppressed tumor growth when compared with control or TelomeKiller injection alone. Analysis of the tumor macroscopic appearance showed that combination therapy-treated tumors were small with surface scar tissues (Fig. 5D). Upon histopathologic analysis, large necrotic areas were observed in combination therapy-treated tumors, but not in control, TelomeKiller-treated or light irradiation-treated tumors (Fig. 5E). These results suggested that combination therapy of TelomeKiller and light irradiation efficiently eliminated tumor cells.

In vivo ablation of lymph node metastasis by the combination of TelomeKiller infection and light irradiation

Finally, we investigated whether intratumoral injection of TelomeKiller in combination with laser irradiation could ablate regional lymph node metastasis in a colorectal cancer HCT116-GFP xenograft tumor model. We recently established an orthotopic early rectal cancer xenograft model with spontaneous lymph node metastasis by implantation of GFP-labeled HCT116-GFP cells (17). Using this animal model, TelomeKiller was injected directly into the rectal HCT116-GFP tumors, which grew to a diameter of about 5 mm with GFP-labeled lymph node metastasis (Fig. 6A). Three days after virus injection, KillerRed and GFP-expressing metastatic lymph nodes were irradiated with a yellow-orange laser (Fig. 6B). Twenty-one days after virus injection, GFP-positive metastatic lymph nodes decreased in size in four of four mice that received both the TelomeKiller injection and laser irradiation. In contrast, GFP-positive metastatic lymph nodes

Figure 4.
Time-dependent KillerRed upregulation and laser irradiation-induced decreased cell viability in human cancer cells infected with TelomeKiller. A, expression of the KillerRed protein in H1299 cells infected with a replication-deficient Ad-KillerRed (Ad-KR) virus or a telomerase-specific conditionally replicating TelomeKiller (CRAd-KR) virus at an MOI of 100 for 72 hours. Parental H1299 cells and KillerRed-expressing stable transfectants H1299-KillerRed (H1299-KR) were used as the negative and positive control, respectively. Cell lysates were subjected to Western blot analysis with an anti-KillerRed antibody. β-Actin was assayed as a loading control. B, H1299, HCT116, and HT-29 cells were infected with TelomeKiller at an MOI of 100 for 48 hours. After infection, the virus-infected cells were irradiated with green light for 60 min. Photobleaching and morphologic changes were evaluated using fluorescent microscope (IX71; Olympus). Scale bar, 200 μm. C, H299, HCT116, and HT-29 cells were infected with TelomeKiller at the indicated MOIs for 48 hours and cell viability was measured using the XTT assay immediately after irradiation with or without green light for 60 minutes. Cell viability was calculated relative to that of the mock-infected group, which was set at 100%. Cell viability data are expressed as mean values ± SD (n = 5). Statistical significance was determined using Student t test. *, P < 0.05.
increased in size in five of six mice that received TelomeKiller injection without laser irradiation. The nontreated control group demonstrated enlargement of GFP-positive metastatic lymph nodes in three of three mice (Fig. 6C and D). The GFP fluorescence intensity of metastatic lymph nodes was decreased in TelomeKiller+PDT group compared with control and TelomeKiller groups, although there was no significant difference (Supplementary Fig. S2). These results suggested that TelomeKiller in combination with light irradiation induced an antitumor effect against regional lymph node metastasis.

Discussion

PDT is a promising minimally invasive anticancer therapy that induces photosensitizer-mediated cell death in combination with light irradiation. Although some kinds of conventional photosensitizers have been systemically administered for PDT in clinical settings (2), the therapeutic potential of PDT is often reduced by the lack of a tumor-specific delivery system for the photosensitizer. In this study, we developed a tumor-specific virus-mediated delivery system for the photosensitive cytotoxic KillerRed, by using a telomerase-specific conditionally replicating TelomeKiller. Tumor-specific replicative TelomeKiller induced much higher KillerRed expression compared with replication-defective Ad-KillerRed. TelomeKiller efficiently induced in vitro and in vivo antitumor effects in combination with light irradiation. Moreover, the formation of metastatic lymph nodes was also suppressed in TelomeKiller-treated tumors when combined with light irradiation. Thus, this tumor-specific replicating virus-mediated KillerRed delivery system is a promising PDT strategy for suppression of the growth of primary tumors and regional lymph node metastasis through a KillerRed-mediated phototoxic effect.

A tumor-specific replicating adenovirus-mediated KillerRed delivery system has some advantages compared to conventional photosensitizer. The first advantage is the high tumor selectivity of KillerRed accumulation, which is achieved by using a telomerase-specific replicating adenovirus. Although systemic administration of conventional photosensitizer often causes light-induced adverse effects because of photosensitizer accumulation in normal tissues, TelomeKiller would reduce the risk of a photosensitivity disorder owing to the tumor-specific KillerRed accumulation. The second advantage is the high and prolonged KillerRed accumulation that

Figure 5.
Antitumor effect of TelomeKiller in subcutaneous HCT116 xenograft tumor model. A, expression of red fluorescence in mice with bilateral HCT116 xenograft tumors injected with PBS (R, right tumor) or TelomeKiller (L, left tumor). B, macroscopic appearance and distribution of red fluorescence in HCT116 tumors injected with PBS or TelomeKiller. Scale bar, 2 mm. C, schedule of treatment and tumor growth curve of the subcutaneous HCT116 xenograft tumor model. Tumor growth is expressed as the mean tumor volume ± SE (n = 4 or 5). Statistical significance was determined using Student t test. *, P < 0.05; n.s., not significant. D, macroscopic appearance of all isolated tumors in each group. E, histopathologic examination of excised tumors stained with hematoxylin and eosin. Left scale bar, 500 μm. Right scale bar, 100 μm. PDT, photodynamic therapy.
can be achieved by using a replication-competent adenovirus. TelomeKiller increases KillerRed expression in a time-dependent manner by virus replication. In contrast, the accumulation of conventional photosensitizer in tumor cells would decrease in a time-dependent manner after administration. The third advantage is the profound dual antitumor effects mediated by KillerRed-mediated cell death and virus-mediated cell lysis. TelomeKiller suppressed the viability of non-irradiated human cancer cells and light irradiation significantly enhanced the antitumor effect of TelomeKiller. In contrast, the therapeutic potential of conventional photosensitizer-based PDT depends mainly on the photosensitizer-mediated cytotoxic effect upon light irradiation (2). Taking these possible advantages into consideration, a TelomeKiller-based PDT strategy would induce a more profound antitumor effect compared to conventional PDT through KillerRed-mediated phototoxicity and virus-mediated oncolysis.

Regarding the mechanism underlying the KillerRed-induced cytotoxic effect, we observed the involvement of intracellular ROS generation and apoptosis induction. Previous reports have suggested that light-mediated KillerRed activation induces ROS generation (3, 5) and apoptosis (5, 7) and these data are consistent with our results. Analysis of KillerRed structure by an X-ray (19) and a high-resolution crystallographic study (20) revealed that a water-filled channel that reacts with the chromophore is responsible for the generation of ROS, which is mainly composed of singlet oxygen (3, 21). The intracellular localization of KillerRed that generates ROS is an especially critical factor for KillerRed-mediated cell cytotoxicity. Williams and colleagues (22) recently showed that KillerRed expression in mitochondria induces only organelle fragmentation, but that its expression in the plasma membrane induces cell death upon light irradiation of the neurons of Caenorhabditis elegans. Consistent with these data, a cell membrane-bound KillerRed expression induces apoptotic cell death upon light irradiation in zebrafish (23) and Xenopus laevis (24). In this study, we used a cell membrane-targeted KillerRed expression vector for the plasmid-based transfection assay and for the development of the Ad-KillerRed and TelomeKiller viruses. Thus, the destruction of cell membrane by KillerRed-induced ROS generation may be the mechanism by which it induces apoptosis in human cancer cells.

Conventional photosensitizer-mediated PDT is limited to early-stage tumors without metastatic regions in clinical settings (2). However, in combination with light irradiation, TelomeKiller significantly suppressed the growth of not only the subcutaneous xenograft tumor but also of lymph node metastasis. These findings suggest that TelomeKiller-based PDT is a promising antitumor strategy for advanced cancer patients with metastatic tumors.
previously reported that intratumoral injection of a telomerase-specific replication-competent adenovirus Telomelysin suppressed the growth of a subcutaneous xenograft tumor (10) and of lymph node metastasis of an orthotopic colorectal cancer model (17, 25). Moreover, an GFP-expressing Telomelysin (OBP-301, Telomés-can) could induce tumor-specific GFP accumulation in the metastatic regions at lymph nodes (13, 26), liver (27), and peritoneal cavities (28) of colorectal tumor-bearing mice. These findings strongly suggest that a TelomeKiller-based PDT strategy is a useful anticancer strategy to eliminate metastatic tumors.

There are some issues that remain to be resolved for clinical application of TelomeKiller in PDT. The first issue is the presence of adenovirus-neutralizing antibody. Clinical studies of the tumor suppressor p53-expressing replication-deficient adenovirus, Ad-p53, have already shown that administration of Ad-p53 by intratumoral, intraperitoneal, or intravascular injection is a safe and feasible antitumor therapy (18), whereas the therapeutic potential of its systemic intravenous administration is less than ideal, because an injected adenovirus vector is attenuated by neutralizing antibody in the blood circulation. Recently, it has been reported that a pH-responsive charge reversal polymeric complex could be successfully used to deliver plasmid DNA of KillerRed to tumors in athymic nude mice following systemic administration (29); however, as PDT itself is a local therapy because the irradiation field is limited, the regional spread of intratumorally injected TelomeKiller might be sufficient to induce the therapeutic benefit. The second issue is the development of light irradiation devices for optimal KillerRed activation. Although yellow-orange light with an excitation wavelength of 585 nm is required to activate KillerRed, yellow-orange light cannot reach deeper than 2 mm in tissues (2). Therefore, the therapeutic target of a TelomeKiller-based PDT strategy would be limited to primary tumors and to metastatic regions at superficial areas where light irradiation can reach. In contrast, long time and frequent exposure of light irradiation was done to obtain the therapeutic potential of TelomeKiller-based PDT in in vitro and in vivo experiments. As light irradiation alone slightly reduced the tumor volume compared with control group (Fig. 5C), high light irradiation may induce considerable heat generation and the antitumor effect as hyperthermia, probably contributing to the discrepancy of antitumor effect between in vitro and in vivo experiments. Moreover, as high light irradiation-induced photobleaching may attenuate the ROS generation, lower light irradiation may produce more antitumor effect of KillerRed with less photobleaching and more ROS generation. To overcome these limitations, further experiments aimed at developing the more appropriate light irradiation devices are warranted for clinical application of the TelomeKiller-based PDT strategy.

In conclusion, we clearly demonstrated that a telomerase-specific conditionally replicating KillerRed-expressing adenovirus, TelomeKiller, efficiently inhibits cell viability, tumor growth and lymph node metastasis in human cancer cells through a KillerRed-mediated photosensitive cytotoxic effect. A phase I clinical trial of Telomelysin in patients with advanced solid tumors has recently been completed and Telomelysin was well tolerated by these patients (30). Although the cytotoxicity of TelomeKiller in cancer patients remains to be elucidated, a conditionally replicating adenovirus-mediated KillerRed delivery system would provide a novel anticancer strategy to improve the therapeutic potential of PDT.

Disclosure of Potential Conflicts of Interest
H. Tazawa, T. Fujiwara, and H. Mizuguchi are consultants/advisory board members for Oncolys BioPharma Inc. No potential conflicts of interest were disclosed by the other authors.

Authors’ Contributions
Conception and design: H. Tazawa, H. Kishimoto, Y. Urata, S. Kagawa, T. Fujiwara
Development of methodology: H. Tazawa, Y. Hashimoto, N. Narii, H. Mizuguchi
Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.): K. Takehara, H. Tazawa, N. Okada, Y. Hashimoto, H. Mizuguchi
Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis): S. Kikuchi, S. Kuroda, H. Kishimoto, S. Kagawa, T. Fujiwara
Writing, review, and/or revision of the manuscript: K. Takehara, H. Tazawa, T. Fujiwara
Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases): H. Tazawa, S. Kikuchi, Y. Urata, T. Fujiwara
Study supervision: H. Tazawa, H. Kishimoto, Y. Shirakawa, T. Fujiwara

Acknowledgments
The authors thank Tomoko Sueishi for her technical support.

Grant Support
This study was supported by grants from the Ministry of Health, Labour, and Welfare of Japan (to T. Fujiwara; Nos. 10103827, 13801426, and 14525167) and by grants from the Ministry of Education, Culture, Sports, Science and Technology, Japan (T. Fujiwara; No. 25293283).

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received April 29, 2015; revised September 22, 2015; accepted September 25, 2015; published OnlineFirst December 1, 2015.

References
Takehara et al.


Targeted Photodynamic Virotherapy Armed with a Genetically Encoded Photosensitizer

Kiyoto Takehara, Hiroshi Tazawa, Naohiro Okada, et al.

Mol Cancer Ther Published OnlineFirst December 1, 2015.